Design and synthesis of pyridin-2-yloxymethylpiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication

被引：9
|
作者：
Skerlj, Renato [1 ]
Bridger, Gary [2 ]
Zhou, Yuanxi [2 ]
Bourque, Elyse [1 ]
Langille, Jonathan [2 ]
Di Fluri, Maria [2 ]
Bogucki, David [2 ]
Yang, Wen [2 ]
Li, Tongshuang [2 ]
Wang, Letian [2 ]
Nan, Susan [2 ]
Baird, Ian [2 ]
Metz, Markus [1 ]
Darkes, Marilyn [2 ]
Labrecque, Jean [2 ]
Lau, Gloria [1 ]
Fricker, Simon [1 ]
Huskens, Dana [3 ]
Schols, Dominique [3 ]
机构：
[1] Genzyme Corp, Waltham, MA 02451 USA
[2] AnorMED Inc, Langley, BC V2Y 1N5, Canada
[3] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2011年 / 21卷 / 08期
关键词：
CCR5; Chemokine receptor; HIV-1; Schering C; IMMUNODEFICIENCY-VIRUS TYPE-1; BIOLOGICAL EVALUATION; RECEPTOR; MARAVIROC; AMD3100;
D O I：
10.1016/j.bmcl.2011.02.058
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
A novel series of CCR5 antagonists were identified based on the redesign of Schering C. An SAR was established based on inhibition of CCR5 (RANTES) binding and these compounds exhibited potent inhibition of R5 HIV-1 replication in peripheral blood mononuclear cells. (C) 2011 Elsevier Ltd. All rights reserved.
引用
收藏
页码：2450 / 2455
页数：6
相关论文
共 34 条
  • [1] Design and synthesis of pyridin-2-ylmethylaminopiperidin-1-ylbutyl amide CCR5 antagonists that are potent inhibitors of M-tropic (R5) HIV-1 replication
    Skerlj, Renato
    Bridger, Gary
    Zhou, Yuanxi
    Bourque, Elyse
    McEachern, Ernest
    Langille, Jonathan
    Harwig, Curtis
    Veale, Duane
    Yang, Wen
    Li, Tongshong
    Zhu, Yongbao
    Bey, Michael
    Baird, Ian
    Sartori, Michael
    Metz, Markus
    Mosi, Renee
    Nelson, Kim
    Bodart, Veronique
    Wong, Rebecca
    Fricker, Simon
    Mac Farland, Ron
    Huskens, Dana
    Schols, Dominique
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (23) : 6950 - 6954
  • [2] Mitigating hERG Inhibition: Design of Orally Bioavailable CCR5 Antagonists as Potent Inhibitors of R5 HIV-1 Replication
    Skerlj, Renato
    Bridger, Gary
    Zhou, Yuanxi
    Bourque, Elyse
    McEachern, Ernest
    Danthi, Sanjay
    Langille, Jonathan
    Harwig, Curtis
    Veale, Duane
    Carpenter, Bryon
    Ba, Tuya
    Bey, Michael
    Baird, Ian
    Wilson, Trevor
    Metz, Markus
    MacFarland, Ron
    Mosi, Renee
    Bodart, Veronique
    Wong, Rebecca
    Fricker, Simon
    Huskens, Dana
    Schols, Dominique
    ACS MEDICINAL CHEMISTRY LETTERS, 2012, 3 (03): : 216 - 221
  • [3] Design of Substituted lmidazolidinylpiperidinylbenzoic Acids as Chemokine Receptor 5 Antagonists: Potent Inhibitors of R5 HIV-1 Replication
    Skerlj, Renato
    Bridge, Gary
    Zhou, Yuanxi
    Bourque, Elyse
    McEachern, Ernest
    Metz, Markus
    Harwig, Curtis
    Li, Tong-Shuang
    Yang, Wen
    Bogucki, David
    Zhu, Yongbao
    Langille, Jonathan
    Veale, Duane
    Ba, Tuya
    Bey, Michael
    Baird, Ian
    Kaller, Alan
    Krumpak, Maria
    Leitch, David
    Satori, Michael
    Vocadlo, Krystyna
    Guay, Danielle
    Nan, Susan
    Yee, Helen
    Crawford, Jason
    Chen, Gang
    Wilson, Trevor
    Carpenter, Bryon
    Gauthier, David
    MacFarland, Ron
    Mosi, Renee
    Bodart, Veronique
    Wong, Rebecca
    Fricker, Simon
    Schols, Dominique
    JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (20) : 8049 - 8065
  • [4] The EBI2 receptor is coexpressed with CCR5 in CD4+ T cells and boosts HIV-1 R5 replication
    Guigues, Adeline
    Gimenez, Sandrine
    Mettling, Clement
    Maurel, Damien
    Doumazane, Etienne
    Prezeau, Laurent
    Francois, Vincent
    Corbeau, Pierre
    AIDS, 2024, 38 (10) : 1449 - 1459
  • [5] Preferential recognition of monomeric CCR5 expressed in cultured cells by the HIV-1 envelope glycoprotein gp120 for the entry of R5 HIV-1
    Nakano, Yusuke
    Monde, Kazuaki
    Terasawa, Hiromi
    Yuan, Yuzhe
    Yusa, Keisuke
    Harada, Shinji
    Maeda, Yosuke
    VIROLOGY, 2014, 452 : 117 - 124
  • [6] Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication
    Skerlj, Renato
    Bridger, Gary
    McEachern, Ernest
    Harwig, Curtis
    Smith, Chris
    Kaller, Alan
    Veale, Duane
    Yee, Helen
    Skupinska, Krystyna
    Wauthy, Rossana
    Wang, Letian
    Baird, Ian
    Zhu, Yongbao
    Burrage, Kate
    Yang, Wen
    Sartori, Michael
    Huskens, Dana
    De Clercq, Erik
    Schols, Dominique
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1414 - 1418
  • [7] CCR5 density levels on primary CD4 T cells impact the replication and Enfuvirtide susceptibility of R5 HIV-1
    Heredia, Alonso
    Gilliam, Bruce
    DeVico, Anthony
    Le, Nhut
    Bamba, Douty
    Flinko, Robin
    Lewis, George
    Gallo, Robert C.
    Redfield, Robert R.
    AIDS, 2007, 21 (10) : 1317 - 1322
  • [8] CXCR4 and CCR5 ligands cooperate in monocyte and lymphocyte migration and in inhibition of dual-tropic (R5/X4) HIV-1 infection
    Gouwy, Mieke
    Struyf, Sofie
    Berghmans, Nele
    Vanormelingen, Christophe
    Schols, Dominique
    Van Damme, Jo
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2011, 41 (04) : 963 - 973
  • [9] Design and synthesis of caffeoyl-anilides as portmanteau inhibitors f HIV-1 integrase and CCR5
    Bodiwala, Hardik S.
    Sabde, Sudeep
    Gupta, Pawan
    Mukherjee, Ruchira
    Kumar, Rajender
    Garg, Prabha
    Bhutani, Kamlesh Kumar
    Mitra, Debashis
    Singh, Inder Pal
    BIOORGANIC & MEDICINAL CHEMISTRY, 2011, 19 (03) : 1256 - 1263
  • [10] Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1
    Tallant, Matthew D.
    Duan, Maosheng
    Freeman, George A.
    Ferris, Robert G.
    Edelstein, Mark P.
    Kazmierski, Wieslaw M.
    Wheelan, Pat J.
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2011, 21 (05) : 1394 - 1398
1234